Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc, a life sciences company involved in developing cancer treatments and diagnostics, has appointed Peel Hunt LLP as its Nominated Adviser and sole broker. The company is known for its two proprietary platforms, pre|CISION™ and Affimer®, targeting oncology with a focus on enhancing the precision and reducing the toxicity of drug therapies. Avacta’s leading drug, AVA6000, has entered Phase 1 studies and is demonstrating promising improvements over traditional treatments.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
